Page last updated: 2024-09-04

naproxen and sulfathiazole

naproxen has been researched along with sulfathiazole in 5 studies

Compound Research Comparison

Studies (naproxen)	Trials (naproxen)	Recent Studies (post-2010) (naproxen)	Studies (sulfathiazole)	Trials (sulfathiazole)	Recent Studies (post-2010) (sulfathiazole)
4,551	1,057	1,429	656	4	89

Protein Interaction Comparison

Protein	Taxonomy	sulfathiazole (IC50)
Dihydropteroate synthase	Escherichia coli K-12	2.5
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	2.5
Transcriptional activator protein LasR	Pseudomonas aeruginosa PAO1	9

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Strassburg, CP; Tukey, RH	1
Chang, TK; Ensom, MH; Kiang, TK	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Kuentz, M; Niederquell, A	1

Reviews

3 review(s) available for naproxen and sulfathiazole

Article	Year
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual review of pharmacology and toxicology, 2000, Volume: 40 Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic	2000
UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & therapeutics, 2005, Volume: 106, Issue:1 Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic	2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

2 other study(ies) available for naproxen and sulfathiazole

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Biorelevant dissolution of poorly soluble weak acids studied by UV imaging reveals ranges of fractal-like kinetics. International journal of pharmaceutics, 2014, Mar-10, Volume: 463, Issue:1 Topics: Celecoxib; Chemistry, Pharmaceutical; Hydrogen-Ion Concentration; Ketoprofen; Kinetics; Microscopy, Electron, Scanning; Naproxen; Powder Diffraction; Pyrazoles; Solubility; Spectrum Analysis, Raman; Sulfathiazole; Sulfathiazoles; Sulfonamides; X-Ray Diffraction	2014

Article

Year

FDA-approved drug labeling for the study of drug-induced liver injury.

Drug discovery today, 2011, Volume: 16, Issue:15-16

Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011

Biorelevant dissolution of poorly soluble weak acids studied by UV imaging reveals ranges of fractal-like kinetics.

International journal of pharmaceutics, 2014, Mar-10, Volume: 463, Issue:1

Topics: Celecoxib; Chemistry, Pharmaceutical; Hydrogen-Ion Concentration; Ketoprofen; Kinetics; Microscopy, Electron, Scanning; Naproxen; Powder Diffraction; Pyrazoles; Solubility; Spectrum Analysis, Raman; Sulfathiazole; Sulfathiazoles; Sulfonamides; X-Ray Diffraction

2014